Swedish Orphan and Dongbao to Form Commercial Alliance
In such an alliance, Swedish Orphan Biovitrum would be the marketing and sales partner of choice for Dongbao's pipeline of Biopharmaceuticals and other drugs in Europe and Dongbao would be the marketing and sales partner of choice for the company marketed and pipeline products in China.
The commercial alliance would be a partnership where both parties will benefit in two ways. First, each party secures a marketing and sales partner for its own products in an important new territory, China in the case of Swedish Orphan Biovitrum and Europe in the case of Dongbao. Second, each party gains access to a new portfolio of exciting products for its home markets.
Swedish Orphan Biovitrum intends to deepen its collaboration with Dongbao, including its affiliate Rechon Life Science Group, as regards manufacturing services.
Martin Nicklasson, CEO of Swedish Orphan Biovitrum, said: “We are very pleased to have identified a partner in Dongbao with a successful track record of selling high value biotechnology products in China. Dongbao has a deep understanding of biotechnology products from a manufacturing and clinical development perspective.”
Will the companies benefit with the alliance?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.